Dr. James Chimenti is the co-principle investigator at Somerset Medical Center of a clinical trial being run by the National Cancer Institute to determine which type of radiation treatment is best for patients after they have undergone surgery to resect a metastatic brain tumor. The study, N107C, is a phase III trial of post-surgical stereotactic radiosurgery (SRS) compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease. Traditionally, patients who have undergone surgery to resect a metastatic brain tumor have received WBRT in an effort to treat any residual disease. WBRT delivers radiation to a wide area in the brain, including parts that may not be currently involved with tumor. This can lead to a decline in cognitive function and other side effects. SRS delivers high dose radiation only to the area of resection and any other tumor, sparing parts of the brain not involved with tumor. This may miss areas of microscopic disease that can progress to a larger tumor. The goal of the study is to determine whether there is improved overall survival, cognitive function, quality of life, and tumor recurrence with either technique. Patients that have been diagnosed with a metastatic brain tumor that are interested in participating in this clinical trial can contact us at 732-302-1720.